MA39347B2 - Protéines de fusion d'uti - Google Patents
Protéines de fusion d'utiInfo
- Publication number
- MA39347B2 MA39347B2 MA39347A MA39347A MA39347B2 MA 39347 B2 MA39347 B2 MA 39347B2 MA 39347 A MA39347 A MA 39347A MA 39347 A MA39347 A MA 39347A MA 39347 B2 MA39347 B2 MA 39347B2
- Authority
- MA
- Morocco
- Prior art keywords
- fusion proteins
- uti fusion
- uti
- proteins
- producing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des protéines de fusion d'uti, des séquences d'adn pour produire ces protéines, et des compositions pharmaceutiques et des méthodes d'utilisation correspondantes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461943617P | 2014-02-24 | 2014-02-24 | |
PCT/US2015/017152 WO2015127391A1 (fr) | 2014-02-24 | 2015-02-23 | Protéines de fusion d'uti |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39347A1 MA39347A1 (fr) | 2018-06-29 |
MA39347B2 true MA39347B2 (fr) | 2020-05-29 |
Family
ID=52629709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39347A MA39347B2 (fr) | 2014-02-24 | 2015-02-23 | Protéines de fusion d'uti |
Country Status (37)
Country | Link |
---|---|
US (4) | US9856310B2 (fr) |
EP (2) | EP3110434B1 (fr) |
JP (4) | JP6574431B2 (fr) |
KR (2) | KR20220151005A (fr) |
CN (2) | CN106232135B (fr) |
AR (1) | AR101597A1 (fr) |
AU (4) | AU2015218704B2 (fr) |
BR (1) | BR112016019390B1 (fr) |
CA (2) | CA2939639C (fr) |
CL (1) | CL2016002136A1 (fr) |
CR (1) | CR20160444A (fr) |
CY (1) | CY1120997T1 (fr) |
DK (1) | DK3110434T3 (fr) |
DO (1) | DOP2016000202A (fr) |
EA (2) | EA202091567A1 (fr) |
EC (1) | ECSP16076535A (fr) |
ES (1) | ES2700149T3 (fr) |
GE (1) | GEP20196970B (fr) |
HR (1) | HRP20182029T1 (fr) |
IL (1) | IL247321B (fr) |
JO (1) | JO3729B1 (fr) |
LT (1) | LT3110434T (fr) |
MA (1) | MA39347B2 (fr) |
MX (3) | MX2016010950A (fr) |
MY (1) | MY178774A (fr) |
NZ (3) | NZ760789A (fr) |
PE (1) | PE20170257A1 (fr) |
PH (1) | PH12016501629A1 (fr) |
PL (1) | PL3110434T3 (fr) |
PT (1) | PT3110434T (fr) |
RS (1) | RS58285B1 (fr) |
SG (2) | SG11201606691QA (fr) |
SI (1) | SI3110434T1 (fr) |
TW (1) | TWI694084B (fr) |
UA (1) | UA118866C2 (fr) |
WO (1) | WO2015127391A1 (fr) |
ZA (1) | ZA201606327B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3110434T3 (pl) * | 2014-02-24 | 2019-01-31 | Takeda Gmbh | Białka fuzyjne uti |
EP3635108A4 (fr) * | 2017-06-07 | 2021-03-31 | Spark Therapeutics, Inc. | Agents d'activation destinés à la transfection de cellules et/ou la production de vecteur raav améliorées |
WO2020106881A1 (fr) * | 2018-11-20 | 2020-05-28 | Diamedica Inc. | Polypeptides d'ulinastatine modifiés |
JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
US11725043B2 (en) | 2020-03-05 | 2023-08-15 | DiaMedica USA Inc. | Ulinastatin polypeptides |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
ES2066033T3 (es) | 1989-05-13 | 1995-03-01 | Bayer Ag | Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. |
US5409895A (en) | 1990-11-13 | 1995-04-25 | Mochida Pharmaceutical Co., Ltd. | Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof |
JP2769083B2 (ja) | 1993-02-22 | 1998-06-25 | 日清食品株式会社 | エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法 |
CA2247888A1 (fr) | 1996-03-11 | 1997-09-18 | Bayer Corporation | Bikunine humaine |
DE19725014A1 (de) | 1997-06-13 | 1998-12-17 | Bayer Ag | Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten |
DK1730191T3 (da) * | 2004-03-30 | 2011-10-17 | Glaxo Group Ltd | Immunglobulin som binder HOSM |
MX2007001638A (es) | 2004-08-11 | 2009-02-12 | Trubion Pharmaceuticals Inc | Proteinas de fusion del dominio de unión. |
WO2006129849A1 (fr) * | 2005-06-03 | 2006-12-07 | Mochida Pharmaceutical Co., Ltd. | Proteine fusionnee possedant un anticorps anti-cd14 |
PT1981519T (pt) | 2005-12-29 | 2018-02-23 | Dyax Corp | Inibição de protéases |
PL2334705T3 (pl) * | 2008-09-26 | 2017-06-30 | Ucb Biopharma Sprl | Produkty biologiczne |
CN101721699B (zh) * | 2008-10-13 | 2012-11-07 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用 |
CN102580085B (zh) * | 2008-10-13 | 2013-09-18 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗脓毒症药物中的应用 |
MX2011011815A (es) * | 2009-05-05 | 2012-01-27 | Amgen Inc | Mutantes fgf21 y usos de los mismos. |
IL300276B1 (en) * | 2011-04-29 | 2024-07-01 | Univ Washington | Therapeutic nuclease preparations and methods |
US8619331B2 (en) | 2011-07-19 | 2013-12-31 | Xerox Corporation | Simulated paper texture using clear toner and glossmark on texture-less stock |
CN104159926B (zh) * | 2011-12-01 | 2019-02-01 | 圆祥生命科技有限公司 | 补体和vegf途径的蛋白质抑制剂及其使用方法 |
ES2671631T3 (es) * | 2012-04-23 | 2018-06-07 | Nrl Pharma, Inc. | Proteína de fusión de lactoferrina y método para la preparación de la misma |
CN103044554B (zh) * | 2012-05-14 | 2014-08-27 | 旭华(上海)生物研发中心有限公司 | 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用 |
JP2013253079A (ja) * | 2012-05-14 | 2013-12-19 | Xuhua (Shanghai) Biological Research & Development Center Co Ltd | 生物学的に活性なヒト尿中トリプシンインヒビターのFc融合タンパク質並びにその調製および使用 |
PL3110434T3 (pl) * | 2014-02-24 | 2019-01-31 | Takeda Gmbh | Białka fuzyjne uti |
-
2015
- 2015-02-23 PL PL15708411T patent/PL3110434T3/pl unknown
- 2015-02-23 GE GEAP201514277A patent/GEP20196970B/en unknown
- 2015-02-23 EA EA202091567A patent/EA202091567A1/ru unknown
- 2015-02-23 CN CN201580014645.3A patent/CN106232135B/zh active Active
- 2015-02-23 ES ES15708411T patent/ES2700149T3/es active Active
- 2015-02-23 MX MX2016010950A patent/MX2016010950A/es active IP Right Grant
- 2015-02-23 SG SG11201606691QA patent/SG11201606691QA/en unknown
- 2015-02-23 CA CA2939639A patent/CA2939639C/fr active Active
- 2015-02-23 JP JP2016553562A patent/JP6574431B2/ja active Active
- 2015-02-23 EP EP15708411.2A patent/EP3110434B1/fr active Active
- 2015-02-23 CR CR20160444A patent/CR20160444A/es unknown
- 2015-02-23 CN CN201910282497.3A patent/CN110092837B/zh active Active
- 2015-02-23 SI SI201530516T patent/SI3110434T1/sl unknown
- 2015-02-23 AU AU2015218704A patent/AU2015218704B2/en active Active
- 2015-02-23 KR KR1020227037377A patent/KR20220151005A/ko active IP Right Grant
- 2015-02-23 RS RS20181514A patent/RS58285B1/sr unknown
- 2015-02-23 MY MYPI2016703046A patent/MY178774A/en unknown
- 2015-02-23 UA UAA201609101A patent/UA118866C2/uk unknown
- 2015-02-23 EP EP18192690.8A patent/EP3443978A1/fr active Pending
- 2015-02-23 US US15/120,956 patent/US9856310B2/en active Active
- 2015-02-23 NZ NZ760789A patent/NZ760789A/en unknown
- 2015-02-23 WO PCT/US2015/017152 patent/WO2015127391A1/fr active Application Filing
- 2015-02-23 SG SG10201708400QA patent/SG10201708400QA/en unknown
- 2015-02-23 NZ NZ760008A patent/NZ760008A/en unknown
- 2015-02-23 DK DK15708411.2T patent/DK3110434T3/en active
- 2015-02-23 NZ NZ724196A patent/NZ724196A/en unknown
- 2015-02-23 MA MA39347A patent/MA39347B2/fr unknown
- 2015-02-23 LT LTEP15708411.2T patent/LT3110434T/lt unknown
- 2015-02-23 EA EA201691702A patent/EA037256B1/ru unknown
- 2015-02-23 PT PT15708411T patent/PT3110434T/pt unknown
- 2015-02-23 BR BR112016019390-3A patent/BR112016019390B1/pt active IP Right Grant
- 2015-02-23 CA CA3178241A patent/CA3178241A1/fr active Pending
- 2015-02-23 KR KR1020167026429A patent/KR102461210B1/ko active IP Right Grant
- 2015-02-23 PE PE2016001522A patent/PE20170257A1/es unknown
- 2015-08-20 JO JOP/2015/0200A patent/JO3729B1/ar active
- 2015-08-20 AR ARP150102677A patent/AR101597A1/es unknown
- 2015-08-21 TW TW104127393A patent/TWI694084B/zh active
-
2016
- 2016-08-10 DO DO2016000202A patent/DOP2016000202A/es unknown
- 2016-08-16 PH PH12016501629A patent/PH12016501629A1/en unknown
- 2016-08-17 IL IL247321A patent/IL247321B/en active IP Right Grant
- 2016-08-23 MX MX2019013124A patent/MX2019013124A/es unknown
- 2016-08-23 MX MX2024000004A patent/MX2024000004A/es unknown
- 2016-08-24 CL CL2016002136A patent/CL2016002136A1/es unknown
- 2016-09-13 ZA ZA2016/06327A patent/ZA201606327B/en unknown
- 2016-09-23 EC ECIEPI201676535A patent/ECSP16076535A/es unknown
-
2017
- 2017-11-27 US US15/823,398 patent/US10351618B2/en active Active
-
2018
- 2018-12-03 HR HRP20182029TT patent/HRP20182029T1/hr unknown
- 2018-12-18 CY CY181101355T patent/CY1120997T1/el unknown
-
2019
- 2019-02-15 US US16/277,606 patent/US20200040062A1/en not_active Abandoned
- 2019-06-11 JP JP2019109054A patent/JP6938565B2/ja active Active
- 2019-06-25 AU AU2019204448A patent/AU2019204448B2/en active Active
-
2021
- 2021-06-03 US US17/337,922 patent/US20220127334A1/en active Pending
- 2021-08-31 AU AU2021225156A patent/AU2021225156B2/en active Active
- 2021-09-01 JP JP2021142544A patent/JP2022002513A/ja active Pending
-
2023
- 2023-02-16 AU AU2023200875A patent/AU2023200875A1/en active Pending
- 2023-06-30 JP JP2023108024A patent/JP2023123763A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43018B1 (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
EA201890493A1 (ru) | РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ | |
MA40938A (fr) | Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps | |
EA202092435A3 (ru) | Моноклональные антитела против bcma | |
MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
PH12016501791B1 (en) | Muscarinic receptor agonists | |
MA40534B1 (fr) | Inhibiteurs de mk2 et leurs utilisations | |
MA39347B2 (fr) | Protéines de fusion d'uti | |
CY1119489T1 (el) | Υποκατεστημενη πιπεριδυλο-αιθυλο-πυριμιδινη ως αναστολεας της ο-ακυλο τρανσφερασης της γκρελινης | |
EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
MA44008A (fr) | 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
MX2018007219A (es) | Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
MX2017008278A (es) | Producto para el cuidado bucal y metodos para uso y fabricacion de este. | |
TW201613934A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
EA201600122A1 (ru) | Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
EA201691493A1 (ru) | Замещенные n-арилпиридиноны | |
PH12016501326A1 (en) | (s)-3'-methyl-abscisic acid and esters thereof | |
EA201692227A1 (ru) | Производные сложных аминоэфиров | |
PH12017501869A1 (en) | (s)-2'-vinyl-abscisic acid derivatives | |
EA201691203A1 (ru) | Твёрдые формы тенофовира | |
MA39230B1 (fr) | Hexahydrofuropyrroles utilisés comme inhibiteurs de pde1 | |
WO2016138538A3 (fr) | Utilisation thérapeutique d'anticorps de liaison à l'intégrine | |
MA39355A1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
MX2017000318A (es) | Derivados del acido abscisico sustituido en 3'. |